Novacyt (FR:ALNOV)
:ALNOV
Want to see FR:ALNOV full AI Analyst Report?
ALNOV Stock Chart & Stats
€0.40
<€0.01(0.56%)
At close: 4:00 PM EST
€0.40
<€0.01(0.56%)
Day’s Range― - ―
52-Week Range€0.35 - €0.74
Previous CloseN/A
Volume192.22K
Average Volume (3M)141.10K
Market Cap
€26.86M
Enterprise Value€10.38M
Total Cash (Recent Filing)€23.87M
Total Debt (Recent Filing)€11.02M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding72,588,090
10 Day Avg. Volume69,615
30 Day Avg. Volume141,103
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)1.79
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€26.17M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueNovacyt's core revenue model is driven by per-test consumables (PCR/qPCR assay kits and reagents), creating recurring demand and customer stickiness. This structural revenue stream supports predictable mid-term cash flows and makes top-line more durable versus one-off sales.
Recent Revenue And FCF ImprovementMaterial year-over-year revenue and free cash flow improvements indicate operational recovery and better cash conversion. If sustained, these trends reduce refinancing risk and provide resources for R&D and commercial expansion, improving the company’s structural financial position.
Low Financial LeverageLow leverage and a solid equity ratio provide financial flexibility to fund inventory, tender participation, and product development without immediate refinancing. This balance sheet strength cushions operational volatility and supports strategic investments over the medium term.
Bears Say
Persistent UnprofitabilitySustained net losses and negative operating cash flow erode equity and limit internal funding for growth. Over months this forces reliance on external capital, increasing dilution or financing costs, and constrains the company’s ability to scale commercial operations and R&D sustainably.
Very Low Gross MarginAn exceptionally low gross margin implies structural cost or pricing pressure in core assay lines, limiting operating leverage. Persistently thin margins hamper ability to fund SG&A and innovation from operations, making long-term profitability dependent on meaningful margin improvement.
Eroding Balance-sheet BaseDeclining assets and shareholders' equity signal capital erosion from losses or write-downs. This reduces the company’s buffer against shocks, may constrain borrowing capacity, and increases the probability of future equity raises, affecting strategic optionality over the medium term.
Novacyt News
ALNOV FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.35 and its highest was €0.73 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €26.86M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Apr 30, 2026 which is today.
How were Novacyt’s earnings last quarter?
Currently, no data Available
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in FR:ALNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
ALNOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, including successful site consolidation and growth in key business segments, alongside significant financial losses and exceptional costs. While strategic initiatives and R&D investments show promise for future growth, the financial challenges and loss after tax weigh heavily on the current outlook.View all FR:ALNOV earnings summariesTechnical Analysis
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Euromedis Groupe SA
―
Median Technologies
―
Options Prices
Currently, No data available
---